Palette Life Sciences Receives Favorable Post Approval Study Results for Solesta®
SANTA BARBARA, Calif. and STOCKHOLM, Sweden, March 29, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced the results of their Solesta Post Approval Study (PAS).
- SANTA BARBARA, Calif. and STOCKHOLM, Sweden, March 29, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced the results of their Solesta Post Approval Study (PAS).
- The study was a requirement of the Food and Drug Administration (FDA) approval process and was designed to supplement the results of previous Solesta trials.
- This robust clinical data provides physicians and their patients confidence in choosing Solesta as a treatment option for FI, said Simone Howell, Director of Medical Affairs, Palette Life Sciences.
- Palette Life Sciences is a fully integrated life sciences company.